A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): a Minimal Residual Disease (MRD)-driven, Time-limited Approach

Drug Category : Array
Conference Category : Array
Lead Author : Roeker L, et al.
Published Date : 12/12/2021
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2021/12/ASH2021RoekerU2.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top